

12-05-2003

12.1.03

Form PTO-1595 (Rev. 10/02) OMB No. 0651-0027 (exp. 6/30/2005) Patent & Trademark Office



102616107

U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies): Genetic Therapy, Inc.

2. Name and address of receiving party(ies)

Name: Cell Genesys, Inc.

Internal Address:

Additional name(s) of conveying party(ies) attached? Yes No

3. Nature of conveyance:

- Assignment, Merger, Security Agreement, Change of Name, Other

Street Address: 500 Forbes Blvd.

City: SSF State: CA Zip: 94080

Execution Date: 10/1-2/03

Additional name(s) & address(es) attached? Yes No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: N/A

A. Patent Application No.(s) See attached

B. Patent No.(s) See attached

09348258

Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Cell Genesys, Inc.

Internal Address: Intellectual Property

Street Address: 500 Forbes Blvd.

City: SSF State: CA Zip: 94080

6. Total number of applications and patents involved: 15

7. Total fee (37 CFR 3.41).....\$ 600.00

- Enclosed, Authorized to be charged to deposit account

8. Deposit account number:

031184

DO NOT USE THIS SPACE

9. Signature.

12/04/2003 6TON11 00000051 031184 06348258

01 FC:002 600.00 DA

Linda R. Judge, Esq., Reg. No. 42,702

Name of Person Signing

Signature

11/25/03 Date

Total number of pages including cover sheet, attachments, and documents: 27

Mail documents to be recorded with required cover sheet information to: Commissioner of Patents & Trademarks, Box Assignments Washington, D.C. 20231

EXHIBIT A
ASSIGNED APPLICATIONS/PATENTS

DOCKET NUMBER	SERIAL/PATENT NUMBER	FILING/ISSUE DATE	STATUS
GTI 002.0US	08/348,258	11/28/1994	ABANDONED
GTI 002.1US	08/487,992	06/07/1995	ABANDONED
GTI 002.2US	5,998,205	12/07/1999	ISSUED
GTI 002.3US	6,551,587	04/22/2003	ISSUED
GTI 002.4US	10/323,425	12/19/2002	PENDING
GTI 002.5US	10/323,955	12/19/2002	PENDING
GTI 002.6US	10/323,984	12/19/2002	PENDING
GTI 003.0US	08/974,391	11/19/1997	ISSUED
GTI 003.1US	10/602,853	06/24/2003	PENDING
GTI 004.0US	60/270,922	02/23/2001	ABANDONED
GTI 004.1US	60/295,037	06/01/2001	ABANDONED
GTI 004.2US	60/348,670	01/14/2002	ABANDONED
GTI 004.3US	10/081,969	02/22/2002	PENDING
GTI 005.0US	60/270,885	02/23/2001	ABANDONED
GTI 005.1US	10/081,961	02/22/2002	PENDING

ASSIGNMENT

Genetic Therapy, Inc., a corporation organized under the laws of the State of Delaware, with a principal business address of 9 West Watkins Mill Road, Gaithersburg, Maryland 20878, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, does hereby assign to **CELL GENESYS, INC.**, a corporation organized under the laws of the State of Delaware, with a principal business address of 500 Forbes Boulevard, South San Francisco, California 94080, (hereinafter Assignee), its successors, assigns and legal representatives, all its right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to it by local laws or by treaty, including any international convention for the protection of industrial property, in and for all countries of the world, including the United States and its territories and possessions, in and to the invention described in the following:

U.S. Patent Application No. 08/348,258, filed November 28, 1994
(abandoned)

and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such foreign applications and U.S. applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise, and, and in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

GENETIC THERAPY, INC.


Dated: 1 Oct 2003

By Theresa M. Stevens
Theresa M. Stevens
Executive Director
Business Development and Licensing

STATE OF MARYLAND)
) SS:
COUNTY OF MONTGOMERY)

On Oct. 1, 2003, before me, the undersigned, a Notary Public in and for the State of Maryland, personally appeared Theresa M. Stevens personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument, and acknowledged to me that she executed the same in her authorized capacity and that by her signature on the instrument the person or the entity upon behalf of which the person acted executed the instrument.

WITNESS my hand and official seal.



Notary Public

My Commission expires: 8/1/2006

ASSIGNMENT

Genetic Therapy, Inc., a corporation organized under the laws of the State of Delaware, with a principal business address of 9 West Watkins Mill Road, Gaithersburg, Maryland 20878, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, does hereby assign to **CELL GENESYS, INC.**, a corporation organized under the laws of the State of Delaware, with a principal business address of 500 Forbes Boulevard, South San Francisco, California 94080, (hereinafter Assignee), its successors, assigns and legal representatives, all its right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to it by local laws or by treaty, including any international convention for the protection of industrial property, in and for all countries of the world, including the United States and its territories and possessions, in and to the invention described in the following:

U.S. Patent Application No. 08/487,992, filed June 7, 1995 (abandoned)

and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such foreign applications and U.S. applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise, and, and in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

GENETIC THERAPY, INC.

Dated: 1 Oct 2003

By Theresa M. Stevens
Theresa M. Stevens
Executive Director
Business Development and Licensing

STATE OF MARYLAND)
) SS:
COUNTY OF MONTGOMERY)

On Oct. 1, 2003, before me, the undersigned, a Notary Public in and for the State of Maryland, personally appeared Theresa M. Stevens personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument, and acknowledged to me that she executed the same in her authorized capacity and that by her signature on the instrument the person or the entity upon behalf of which the person acted executed the instrument.

WITNESS my hand and official seal.



Notary Public

My Commission expires: 8/1/2006

ASSIGNMENT

Genetic Therapy, Inc., a corporation organized under the laws of the State of Delaware, with a principal business address of 9 West Watkins Mill Road, Gaithersburg, Maryland 20878, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, does hereby assign to **CELL GENESYS, INC.**, a corporation organized under the laws of the State of Delaware, with a principal business address of 500 Forbes Boulevard, South San Francisco, California 94080, (hereinafter Assignee), its successors, assigns and legal representatives, all its right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to it by local laws or by treaty, including any international convention for the protection of industrial property, in and for all countries of the world, including the United States and its territories and possessions, in and to the invention described in the following:

U.S. Patent No. 5,998,205, issued December 7, 1999

and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such foreign applications and U.S. applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise, and, and in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

GENETIC THERAPY, INC.


Dated: 1 Oct 2003

By Theresa M. Stevens
Theresa M. Stevens
Executive Director
Business Development and Licensing

STATE OF MARYLAND)
) SS:
COUNTY OF MONTGOMERY)

On Oct. 1, 2003, before me, the undersigned, a Notary Public in and for the State of Maryland, personally appeared Theresa M. Stevens personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument, and acknowledged to me that she executed the same in her authorized capacity and that by her signature on the instrument the person or the entity upon behalf of which the person acted executed the instrument.

WITNESS my hand and official seal.



Notary Public

My Commission expires: 8/1/2006

ASSIGNMENT

Genetic Therapy, Inc., a corporation organized under the laws of the State of Delaware, with a principal business address of 9 West Watkins Mill Road, Gaithersburg, Maryland 20878, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, does hereby assign to **CELL GENESYS, INC.**, a corporation organized under the laws of the State of Delaware, with a principal business address of 500 Forbes Boulevard, South San Francisco, California 94080, (hereinafter Assignee), its successors, assigns and legal representatives, all its right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to it by local laws or by treaty, including any international convention for the protection of industrial property, in and for all countries of the world, including the United States and its territories and possessions, in and to the invention described in the following:

U.S. Patent No. 6,551,587, issued April 22, 2003

and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such foreign applications and U.S. applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise, and, and in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

GENETIC THERAPY, INC.


Dated: 1 Oct 2003

By Theresa M Stevens
Theresa M. Stevens
Executive Director
Business Development and Licensing

STATE OF MARYLAND)
) SS:
COUNTY OF MONTGOMERY)

On Oct 1, 2003, before me, the undersigned, a Notary Public in and for the State of Maryland, personally appeared Theresa M. Stevens personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument, and acknowledged to me that she executed the same in her authorized capacity and that by her signature on the instrument the person or the entity upon behalf of which the person acted executed the instrument.

WITNESS my hand and official seal.



Notary Public

My Commission expires: 8/1/2006

ASSIGNMENT

Genetic Therapy, Inc., a corporation organized under the laws of the State of Delaware, with a principal business address of 9 West Watkins Mill Road, Gaithersburg, Maryland 20878, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, does hereby assign to **CELL GENESYS, INC.**, a corporation organized under the laws of the State of Delaware, with a principal business address of 500 Forbes Boulevard, South San Francisco, California 94080, (hereinafter Assignee), its successors, assigns and legal representatives, all its right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to it by local laws or by treaty, including any international convention for the protection of industrial property, in and for all countries of the world, including the United States and its territories and possessions, in and to the invention described in the following:

U.S. Patent Application No. 10/323,425, filed December 19, 2002

and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such foreign applications and U.S. applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise, and, and in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

GENETIC THERAPY, INC.


Dated: 1 Oct 2003

By Theresa M. Stevens
Theresa M. Stevens
Executive Director
Business Development and Licensing

STATE OF MARYLAND)
) SS:
COUNTY OF MONTGOMERY)

On Oct. 1, 2003, before me, the undersigned, a Notary Public in and for the State of Maryland, personally appeared Theresa M. Stevens personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument, and acknowledged to me that she executed the same in her authorized capacity and that by her signature on the instrument the person or the entity upon behalf of which the person acted executed the instrument.

WITNESS my hand and official seal.



Notary Public

My Commission expires: 8/1/2006

ASSIGNMENT

Genetic Therapy, Inc., a corporation organized under the laws of the State of Delaware, with a principal business address of 9 West Watkins Mill Road, Gaithersburg, Maryland 20878, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, does hereby assign to **CELL GENESYS, INC.**, a corporation organized under the laws of the State of Delaware, with a principal business address of 500 Forbes Boulevard, South San Francisco, California 94080, (hereinafter Assignee), its successors, assigns and legal representatives, all its right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to it by local laws or by treaty, including any international convention for the protection of industrial property, in and for all countries of the world, including the United States and its territories and possessions, in and to the invention described in the following:

U.S. Patent Application No. 10/323,955, filed December 19, 2002

and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such foreign applications and U.S. applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise, and, and in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

GENETIC THERAPY, INC.

Dated: 1 Oct 2003

By Theresa M. Stevens
Theresa M. Stevens
Executive Director
Business Development and Licensing

STATE OF MARYLAND)
) SS:
COUNTY OF MONTGOMERY)

On Oct 1, 2003, before me, the undersigned, a Notary Public in and for the State of Maryland, personally appeared Theresa M. Stevens personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument, and acknowledged to me that she executed the same in her authorized capacity and that by her signature on the instrument the person or the entity upon behalf of which the person acted executed the instrument.

WITNESS my hand and official seal.

Harold Russell
Notary Public

My Commission expires: 8/1/2006

ASSIGNMENT

Genetic Therapy, Inc., a corporation organized under the laws of the State of Delaware, with a principal business address of 9 West Watkins Mill Road, Gaithersburg, Maryland 20878, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, does hereby assign to **CELL GENESYS, INC.**, a corporation organized under the laws of the State of Delaware, with a principal business address of 500 Forbes Boulevard, South San Francisco, California 94080, (hereinafter Assignee), its successors, assigns and legal representatives, all its right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to it by local laws or by treaty, including any international convention for the protection of industrial property, in and for all countries of the world, including the United States and its territories and possessions, in and to the invention described in the following:

U.S. Patent Application No. 10/323,984, filed December 19, 2002

and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such foreign applications and U.S. applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise, and, and in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

GENETIC THERAPY, INC.

Dated: 1 Oct 2003

By Theresa M. Stevens
Theresa M. Stevens
Executive Director
Business Development and Licensing

STATE OF MARYLAND)
) SS:
COUNTY OF MONTGOMERY)

On Oct. 1, 2003, before me, the undersigned, a Notary Public in and for the State of Maryland, personally appeared Theresa M. Stevens personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument, and acknowledged to me that she executed the same in her authorized capacity and that by her signature on the instrument the person or the entity upon behalf of which the person acted executed the instrument.

WITNESS my hand and official seal.



Notary Public

My Commission expires: 8/1/2006

ASSIGNMENT

Genetic Therapy, Inc., a corporation organized under the laws of the State of Delaware, with a principal business address of 9 West Watkins Mill Road, Gaithersburg, Maryland 20878, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, does hereby assign to **CELL GENESYS, INC.**, a corporation organized under the laws of the State of Delaware, with a principal business address of 500 Forbes Boulevard, South San Francisco, California 94080, (hereinafter Assignee), its successors, assigns and legal representatives, all its right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to it by local laws or by treaty, including any international convention for the protection of industrial property, in and for all countries of the world, including the United States and its territories and possessions, in and to the invention described in the following:

U.S. Patent Application No. 08/974,391, filed November 19, 1997

and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such foreign applications and U.S. applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise, and, and in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

GENETIC THERAPY, INC.

Dated: 1 Oct 2003

By Theresa M Stevens
Theresa M. Stevens
Executive Director
Business Development and Licensing

STATE OF MARYLAND)
) SS:
COUNTY OF MONTGOMERY)

On Oct. 1, 2003, before me, the undersigned, a Notary Public in and for the State of Maryland, personally appeared Theresa M. Stevens personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument, and acknowledged to me that she executed the same in her authorized capacity and that by her signature on the instrument the person or the entity upon behalf of which the person acted executed the instrument.

WITNESS my hand and official seal.



Notary Public

My Commission expires: 8/1/2006

ASSIGNMENT

Genetic Therapy, Inc., a corporation organized under the laws of the State of Delaware, with a principal business address of 9 West Watkins Mill Road, Gaithersburg, Maryland 20878, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, does hereby assign to **CELL GENESYS, INC.**, a corporation organized under the laws of the State of Delaware, with a principal business address of 500 Forbes Boulevard, South San Francisco, California 94080, (hereinafter Assignee), its successors, assigns and legal representatives, all its right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to it by local laws or by treaty, including any international convention for the protection of industrial property, in and for all countries of the world, including the United States and its territories and possessions, in and to the invention described in the following:

U.S. Patent Application No. 10/602,853, filed June 24, 2003

and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such foreign applications and U.S. applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise, and, and in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

GENETIC THERAPY, INC.


Dated: 1 Oct 2003

By Theresa M. Stevens
Theresa M. Stevens
Executive Director
Business Development and Licensing

STATE OF MARYLAND)
) SS:
COUNTY OF MONTGOMERY)

On Oct. 1, 2003, before me, the undersigned, a Notary Public in and for the State of Maryland, personally appeared Theresa M. Stevens personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument, and acknowledged to me that she executed the same in her authorized capacity and that by her signature on the instrument the person or the entity upon behalf of which the person acted executed the instrument.

WITNESS my hand and official seal.



Notary Public

My Commission expires: 8/1/2006

ASSIGNMENT

Novartis AG, a corporation organized under the laws of the Swiss Confederation, with a principal business address of Lichtstrasse 35, CH-4056 Basel, Switzerland, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, does hereby assign to **CELL GENESYS, INC.**, a corporation organized under the laws of the State of Delaware, with a principal business address of 500 Forbes Boulevard, South San Francisco, California 94080, (hereinafter Assignee), its successors, assigns and legal representatives, all its right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to it by local laws or by treaty, including any international convention for the protection of industrial property, in and for all countries of the world, including the United States and its territories and possessions, in and to the invention described in the following:

U.S. Provisional Patent Application No. 60/270,922, filed February 23, 2001 (abandoned)

and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such foreign applications and U.S. applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise, and, and in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

NOVARTIS AG

Dated: October 2, 2003

By  _____
Arthur Canonica
Patent and Trademark Administrator

By  _____
Hans Rudolf Haus
Patent and Trademark Administrator

ASSIGNMENT

Novartis AG, a corporation organized under the laws of the Swiss Confederation, with a principal business address of Lichtstrasse 35, CH-4056 Basel, Switzerland, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, does hereby assign to **CELL GENESYS, INC.**, a corporation organized under the laws of the State of Delaware, with a principal business address of 500 Forbes Boulevard, South San Francisco, California 94080, (hereinafter Assignee), its successors, assigns and legal representatives, all its right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to it by local laws or by treaty, including any international convention for the protection of industrial property, in and for all countries of the world, including the United States and its territories and possessions, in and to the invention described in the following:


U.S. Provisional Patent Application No. 60/295,037, filed June 1, 2001
(abandoned)

and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such foreign applications and U.S. applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise, and, and in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

NOVARTIS AG

Dated: October 2, 2003

By 
Arthur Canonica
Patent and Trademark Administrator

By 
Hans Rudolf Haus
Patent and Trademark Administrator

ASSIGNMENT

Novartis AG, a corporation organized under the laws of the Swiss Confederation, with a principal business address of Lichtstrasse 35, CH-4056 Basel, Switzerland, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, does hereby assign to **CELL GENESYS, INC.**, a corporation organized under the laws of the State of Delaware, with a principal business address of 500 Forbes Boulevard, South San Francisco, California 94080, (hereinafter Assignee), its successors, assigns and legal representatives, all its right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to it by local laws or by treaty, including any international convention for the protection of industrial property, in and for all countries of the world, including the United States and its territories and possessions, in and to the invention described in the following:


U.S. Provisional Patent Application No. 60/348,670, filed January 14, 2002 (abandoned)

and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such foreign applications and U.S. applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise, and, and in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

NOVARTIS AG

Dated: October 2, 2003

By  _____
Arthur Canonica
Patent and Trademark Administrator

By  _____
Hans Rudolf Haus
Patent and Trademark Administrator

ASSIGNMENT

Novartis AG, a corporation organized under the laws of the Swiss Confederation, with a principal business address of Lichtstrasse 35, CH-4056 Basel, Switzerland, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, does hereby assign to **CELL GENESYS, INC.**, a corporation organized under the laws of the State of Delaware, with a principal business address of 500 Forbes Boulevard, South San Francisco, California 94080, (hereinafter Assignee), its successors, assigns and legal representatives, all its right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to it by local laws or by treaty, including any international convention for the protection of industrial property, in and for all countries of the world, including the United States and its territories and possessions, in and to the invention described in the following:

U.S. Patent Application No. 10/081,969, filed February 22, 2002


and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such foreign applications and U.S. applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise, and, and in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

NOVARTIS AG

Dated: October 2, 2003

By 

Arthur Canonica
Patent and Trademark Administrator

By 

Hans Rudolf Haus
Patent and Trademark Administrator

ASSIGNMENT

Novartis AG, a corporation organized under the laws of the Swiss Confederation, with a principal business address of Lichtstrasse 35, CH-4056 Basel, Switzerland, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, does hereby assign to **CELL GENESYS, INC.**, a corporation organized under the laws of the State of Delaware, with a principal business address of 500 Forbes Boulevard, South San Francisco, California 94080, (hereinafter Assignee), its successors, assigns and legal representatives, all its right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to it by local laws or by treaty, including any international convention for the protection of industrial property, in and for all countries of the world, including the United States and its territories and possessions, in and to the invention described in the following:


U.S. Provisional Patent Application No. 60/270,885, filed February 23, 2001 (abandoned)

and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such foreign applications and U.S. applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise, and, and in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

NOVARTIS AG

Dated: October 2, 2003

By 
Arthur Canonica
Patent and Trademark Administrator

By 
Hans Rudolf Haus
Patent and Trademark Administrator

ASSIGNMENT


Novartis AG, a corporation organized under the laws of the Swiss Confederation, with a principal business address of Lichtstrasse 35, CH-4056 Basel, Switzerland, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, does hereby assign to **CELL GENESYS, INC.**, a corporation organized under the laws of the State of Delaware, with a principal business address of 500 Forbes Boulevard, South San Francisco, California 94080, (hereinafter Assignee), its successors, assigns and legal representatives, all its right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to it by local laws or by treaty, including any international convention for the protection of industrial property, in and for all countries of the world, including the United States and its territories and possessions, in and to the invention described in the following:


U.S. Patent Application No. 10/081,961, filed February 22, 2002

and in and to all Convention and Treaty rights of all kinds, in all countries throughout the world, for all such subject matter, including the right to claim for any such foreign applications and U.S. applications any priority rights to which such applications are entitled under international conventions, treaties or otherwise, and, and in and to, all Letters Patent to be obtained for said subject matter by the above application or any continuation, division, continuation-in-part, extension, conversion to 35 USC 111(b) or substitute thereof, and any reissue, reexamination or extension of said Letters Patent.

NOVARTIS AG

Dated: October 2, 2003

By 
Arthur Canonica
Patent and Trademark Administrator

By 
Hans Rudolf Haus
Patent and Trademark Administrator